Drug intelligence / Profile preview

perakizumab

Development stage: Phase 1
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Perakizumab is a human monoclonal antibody that targets interleukin-17A (IL-17A), acting as an IL-17A inhibitor. It was developed by Roche for the treatment of psoriatic arthritis. The drug works by binding to and neutralizing IL-17A, a pro-inflammatory cytokine implicated in the pathogenesis of several autoimmune diseases, including psoriatic arthritis. Perakizumab advanced to phase 1 clinical trials but development was discontinued after this stage[1][2][4].

Other names: perakizumab

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on perakizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on perakizumab.

Explore the full profile